JPRN-jRCTs031220492招募中Unknown
A Randomized, Placebo-Controlled, Double-Blind, Comparative Study of the Central and Peripheral Neurological Effects of dl-Methylephedrine on Athletic Performance - MCPA study
Tateno Amane0 个研究点目标入组 20 人开始时间: 2022年12月7日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 40age old（—）
- 性别
- Male
入选标准
- •1) Subjects who are 20 years old or older and younger than 40 years old when obtaining consents
- •2) Subjects with no history of psychiatric and/or neurological disorders
- •3) Subjects with normal BMI (18.5 - 25)
- •4) Subjects without the history of smoking
- •5) Subjects who have the ability to provide informed consent and adhere to the protocol
排除标准
- •Research subjects who fall into any one of the following categories will be excluded from this study
- •1) Subjects receiving catecholamine preparations (adrenaline, isoproterenol, etc.)
- •2) Subjects with a history of hypersensitivity to compounds of similar chemical structure (preparations containing ephedrine hydrochloride or methyl ephedrine hydrochloride)
- •3) Patients with a history of insomnia, dizziness, weakness, tremor, or irregular heartbeat caused by sympathomimetic drugs
- •4) Patients who have been diagnosed with any of the following diseases
- •(hyperthyroidism, hypertension, cardiac disease, diabetes, benign prostatic hypertrophy, renal dysfunction, disease causing urinary retention, glaucoma or other diseases causing high intraocular pressure)
- •5) Patients with a history of gastrointestinal symptoms upon lactose intake
- •6) Patients who have received drug therapy within one week prior to the scheduled date of the first dose of medication
- •7) Those who are scheduled to participate in the brain function test and are wearing a device (cardiac pacemaker, cerebral aneurysm clip, etc.) that is affected by the high magnetic field of the MRI machine, or have a machine or metal in their body
- •8) Persons who have consumed caffeine within 2 days prior to the motor function test and brain function test, or alcohol at least one day prior to the test
- •9) Those who have been exposed to more than 15 mSv (millisievert) per year due to radiation exposure from work or radiation therapy (15 mSv is equivalent to 3-4 x-rays of the stomach)
- •10) Persons who have received radiopharmaceuticals between two days prior to the PET scan and the day after the PET scan, or are scheduled to receive such contrast media or radiopharmaceuticals on the day after the PET scan.
- •11) Persons who wish to participate in a competition
- •12) Persons who do not agree to be notified of the results of the tests obtained in this study, if they are determined to be in need of treatment by the principal investigator or a physician in charge of the study.
- •13) Any other person who is deemed inappropriate to participate in this study by the investigator.
研究者
相似试验
已完成
不适用
Effect of Test Products on Immune Markers and Gut Health In Elderly PopulatioCTRI/2020/03/023865Tata Chemicals Ltd199
已完成
3 期
A clinical trial to study the effect of Apremilast Tablets in the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.CTRI/2016/10/007345Glenmark Pharmaceuticals Ltd
招募中
4 期
A Study for Assessing the Efficacy and Safety of ParActin® in Individuals with Upper respiratory tract infectionsCTRI/2024/04/065020Vedic Lifesciences Pvt. Ltd
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 16.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-022576-30-CZRadius Health, Inc.2,400
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-022576-30-LTRadius Health, Inc.2,400